Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities

Eric van Cutsem, Gerald Prager, Daniel Sargent, Annette T. Byrne, Heinrich J. Huber, Gary Middleton, Khurum Khan, Leticia De Mattos-Arruda, Thomas Seufferlein

Research output: Contribution to journalReview article

Abstract

The search for molecular biomarkers that predict the likely response to targeted treatments for metastatic colorectal cancer (mCRC) has yielded many promising candidates, yet only the (K)RAS mutation has so far been incorporated into clinical practice. Other promising biomarkers of response to anti-angiogenic agents and the multikinase inhibitor, regorafenib, are currently under investigation in ongoing studies. While a growing understanding of cancer signaling pathways in mCRC presents multiple opportunities for the development of tumor-targeted therapies, inter- and intra-tumor heterogeneity and the dynamic process of tumor evolution during treatment present major challenges to biomarker research and drug development. Overcoming these challenges requires the application of novel approaches to the assessment of biomarkers and innovative clinical trials that employ statistical approaches that maximize efficiency and minimize exposure to underperforming treatments. Ongoing, contemporary biomarker-driven studies in mCRC have already yielded salient lessons that will inform the design of future studies. These will also benefit from the combined expertise of major research consortia using systems biology approaches to the identification and validation of predictive biomarkers in mCRC. With such a powerful global commitment to biomarker research in mCRC, there seems little doubt that before too long, new predictive biomarkers will be available to help guide clinical decision-making in mCRC, ensuring the right treatment is selected for the right patient at the right time.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalJournal of OncoPathology
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Colorectal Neoplasms
Biomarkers
Neoplasms
Research
Systems Biology
Patient Rights
Clinical Trials
Mutation
Pharmaceutical Preparations

Keywords

  • Angiopredict
  • Biomarkers
  • FOCUS4
  • Metastatic colorectal cancer
  • OncoTrack
  • PROSPECT-R
  • SPECTAcolor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

van Cutsem, E., Prager, G., Sargent, D., Byrne, A. T., Huber, H. J., Middleton, G., ... Seufferlein, T. (2014). Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities. Journal of OncoPathology, 2(4), 37-45. https://doi.org/10.13032/tjop.2052-5931.100113

Biomarker-driven studies in metastatic colorectal cancer (mCRC) : Challenges and opportunities. / van Cutsem, Eric; Prager, Gerald; Sargent, Daniel; Byrne, Annette T.; Huber, Heinrich J.; Middleton, Gary; Khan, Khurum; De Mattos-Arruda, Leticia; Seufferlein, Thomas.

In: Journal of OncoPathology, Vol. 2, No. 4, 01.01.2014, p. 37-45.

Research output: Contribution to journalReview article

van Cutsem, E, Prager, G, Sargent, D, Byrne, AT, Huber, HJ, Middleton, G, Khan, K, De Mattos-Arruda, L & Seufferlein, T 2014, 'Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities', Journal of OncoPathology, vol. 2, no. 4, pp. 37-45. https://doi.org/10.13032/tjop.2052-5931.100113
van Cutsem, Eric ; Prager, Gerald ; Sargent, Daniel ; Byrne, Annette T. ; Huber, Heinrich J. ; Middleton, Gary ; Khan, Khurum ; De Mattos-Arruda, Leticia ; Seufferlein, Thomas. / Biomarker-driven studies in metastatic colorectal cancer (mCRC) : Challenges and opportunities. In: Journal of OncoPathology. 2014 ; Vol. 2, No. 4. pp. 37-45.
@article{6d474b38f31e4404b2514a8840b6e183,
title = "Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities",
abstract = "The search for molecular biomarkers that predict the likely response to targeted treatments for metastatic colorectal cancer (mCRC) has yielded many promising candidates, yet only the (K)RAS mutation has so far been incorporated into clinical practice. Other promising biomarkers of response to anti-angiogenic agents and the multikinase inhibitor, regorafenib, are currently under investigation in ongoing studies. While a growing understanding of cancer signaling pathways in mCRC presents multiple opportunities for the development of tumor-targeted therapies, inter- and intra-tumor heterogeneity and the dynamic process of tumor evolution during treatment present major challenges to biomarker research and drug development. Overcoming these challenges requires the application of novel approaches to the assessment of biomarkers and innovative clinical trials that employ statistical approaches that maximize efficiency and minimize exposure to underperforming treatments. Ongoing, contemporary biomarker-driven studies in mCRC have already yielded salient lessons that will inform the design of future studies. These will also benefit from the combined expertise of major research consortia using systems biology approaches to the identification and validation of predictive biomarkers in mCRC. With such a powerful global commitment to biomarker research in mCRC, there seems little doubt that before too long, new predictive biomarkers will be available to help guide clinical decision-making in mCRC, ensuring the right treatment is selected for the right patient at the right time.",
keywords = "Angiopredict, Biomarkers, FOCUS4, Metastatic colorectal cancer, OncoTrack, PROSPECT-R, SPECTAcolor",
author = "{van Cutsem}, Eric and Gerald Prager and Daniel Sargent and Byrne, {Annette T.} and Huber, {Heinrich J.} and Gary Middleton and Khurum Khan and {De Mattos-Arruda}, Leticia and Thomas Seufferlein",
year = "2014",
month = "1",
day = "1",
doi = "10.13032/tjop.2052-5931.100113",
language = "English (US)",
volume = "2",
pages = "37--45",
journal = "Journal of OncoPathology",
issn = "2052-5931",
publisher = "Good Health Trading Limited",
number = "4",

}

TY - JOUR

T1 - Biomarker-driven studies in metastatic colorectal cancer (mCRC)

T2 - Challenges and opportunities

AU - van Cutsem, Eric

AU - Prager, Gerald

AU - Sargent, Daniel

AU - Byrne, Annette T.

AU - Huber, Heinrich J.

AU - Middleton, Gary

AU - Khan, Khurum

AU - De Mattos-Arruda, Leticia

AU - Seufferlein, Thomas

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The search for molecular biomarkers that predict the likely response to targeted treatments for metastatic colorectal cancer (mCRC) has yielded many promising candidates, yet only the (K)RAS mutation has so far been incorporated into clinical practice. Other promising biomarkers of response to anti-angiogenic agents and the multikinase inhibitor, regorafenib, are currently under investigation in ongoing studies. While a growing understanding of cancer signaling pathways in mCRC presents multiple opportunities for the development of tumor-targeted therapies, inter- and intra-tumor heterogeneity and the dynamic process of tumor evolution during treatment present major challenges to biomarker research and drug development. Overcoming these challenges requires the application of novel approaches to the assessment of biomarkers and innovative clinical trials that employ statistical approaches that maximize efficiency and minimize exposure to underperforming treatments. Ongoing, contemporary biomarker-driven studies in mCRC have already yielded salient lessons that will inform the design of future studies. These will also benefit from the combined expertise of major research consortia using systems biology approaches to the identification and validation of predictive biomarkers in mCRC. With such a powerful global commitment to biomarker research in mCRC, there seems little doubt that before too long, new predictive biomarkers will be available to help guide clinical decision-making in mCRC, ensuring the right treatment is selected for the right patient at the right time.

AB - The search for molecular biomarkers that predict the likely response to targeted treatments for metastatic colorectal cancer (mCRC) has yielded many promising candidates, yet only the (K)RAS mutation has so far been incorporated into clinical practice. Other promising biomarkers of response to anti-angiogenic agents and the multikinase inhibitor, regorafenib, are currently under investigation in ongoing studies. While a growing understanding of cancer signaling pathways in mCRC presents multiple opportunities for the development of tumor-targeted therapies, inter- and intra-tumor heterogeneity and the dynamic process of tumor evolution during treatment present major challenges to biomarker research and drug development. Overcoming these challenges requires the application of novel approaches to the assessment of biomarkers and innovative clinical trials that employ statistical approaches that maximize efficiency and minimize exposure to underperforming treatments. Ongoing, contemporary biomarker-driven studies in mCRC have already yielded salient lessons that will inform the design of future studies. These will also benefit from the combined expertise of major research consortia using systems biology approaches to the identification and validation of predictive biomarkers in mCRC. With such a powerful global commitment to biomarker research in mCRC, there seems little doubt that before too long, new predictive biomarkers will be available to help guide clinical decision-making in mCRC, ensuring the right treatment is selected for the right patient at the right time.

KW - Angiopredict

KW - Biomarkers

KW - FOCUS4

KW - Metastatic colorectal cancer

KW - OncoTrack

KW - PROSPECT-R

KW - SPECTAcolor

UR - http://www.scopus.com/inward/record.url?scp=85043223846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043223846&partnerID=8YFLogxK

U2 - 10.13032/tjop.2052-5931.100113

DO - 10.13032/tjop.2052-5931.100113

M3 - Review article

AN - SCOPUS:85043223846

VL - 2

SP - 37

EP - 45

JO - Journal of OncoPathology

JF - Journal of OncoPathology

SN - 2052-5931

IS - 4

ER -